127 related articles for article (PubMed ID: 300384)
1. T and B lymphocyte migration into syngeneic tumors.
Elboim CM; Reinisch CL; Schlossman SF
J Immunol; 1977 Mar; 118(3):1042-8. PubMed ID: 300384
[TBL] [Abstract][Full Text] [Related]
2. Distribution of normal T lymphocytes in tumor-bearing rats.
Klobusická M; Koníková E
Neoplasma; 1982; 29(6):727-34. PubMed ID: 6984490
[TBL] [Abstract][Full Text] [Related]
3. Effect of tumor growth on migratory properties of T lymphocytes in rats.
Klobusická M; Koníková E; Novotná L
Neoplasma; 1980; 27(6):675-82. PubMed ID: 6973097
[TBL] [Abstract][Full Text] [Related]
4. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
[TBL] [Abstract][Full Text] [Related]
5. Immune response against P815X2 mastocytoma growing in syngeneic DBA/2 mice. III. Morphometric assessment of the dynamic changes in post-capillary venules as regulatory elements of lymphocyte recirculation in tumor-draining lymph nodes.
Tosi P; Syrjänen K; Cintorino M; Mäntyjärvi R; Luzi P; Miracco C; Laatikainen A; Leoncini L; Santopietro R
Arch Geschwulstforsch; 1987; 57(1):7-15. PubMed ID: 3105513
[TBL] [Abstract][Full Text] [Related]
6. Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice.
Riccobene TA; Miceli RC; Lincoln C; Knight Y; Meadows J; Stabin MG; Sung C
J Nucl Med; 2003 Mar; 44(3):422-33. PubMed ID: 12621010
[TBL] [Abstract][Full Text] [Related]
7. Tumor-specific immune responsiveness of the tumor-bearing host.
Burk MW; Yu S; McKhann CF
Isr J Med Sci; 1976; 12(4-5):360-8. PubMed ID: 939694
[TBL] [Abstract][Full Text] [Related]
8. Effect of thymectomy on tumor development and on T and B lymphocytes in tumor-bearing rats.
Klobusická M; Koníková E; Novotná L
Neoplasma; 1979; 26(4):413-21. PubMed ID: 392324
[TBL] [Abstract][Full Text] [Related]
9. Differences in the migration of B and T lymphocytes: organ-selective localization in vivo and the role of lymphocyte-endothelial cell recognition.
Stevens SK; Weissman IL; Butcher EC
J Immunol; 1982 Feb; 128(2):844-51. PubMed ID: 6976385
[TBL] [Abstract][Full Text] [Related]
10. Studies on T and B lymphocytes in rats bearing methylcholanthrene-induced tumor.
Klobusická M; Kalafut F; Novotná L
Neoplasma; 1978; 25(6):667-77. PubMed ID: 313020
[TBL] [Abstract][Full Text] [Related]
11. Role of adhesion molecules in the immune reaction to M-MSV-induced tumors.
Rosato A; Bronte V; Mandruzzato S; Zambon A; Calderazzo F; Biasi G; Zanovello P; Collavo D
Int J Cancer Suppl; 1992; 7():24-7. PubMed ID: 1385341
[TBL] [Abstract][Full Text] [Related]
12. Matching of chemotherapy to mouse strain and lymphoid tumor type to prevent tumor-induced suppression of specific T- and B-cell functions.
Faanes RB; Merluzzi VJ; Williams N; Tarnowski GS; Ralph P
Cancer Res; 1979 Nov; 39(11):4564-74. PubMed ID: 315269
[TBL] [Abstract][Full Text] [Related]
13. Tumor sponge implantation: an in vivo method for studying syngeneic, primary antitumor lymphocyte responses.
Vallera DA; Mentzer SJ; Maizel SE
Cancer Res; 1982 Feb; 42(2):397-404. PubMed ID: 7055792
[TBL] [Abstract][Full Text] [Related]
14. A role for endogenous IL-12 in tumor immunity: IL-12 is required for the acquisition of tumor-migratory capacity by T cells and the development of T cell-accepting capacity in tumor masses.
Uekusa Y; Gao P; Yamaguchi N; Tomura M; Mukai T; Nakajima C; Iwasaki M; Takeuchi N; Tsujimura T; Nakazawa M; Fujiwara H; Hamaoka T
J Leukoc Biol; 2002 Nov; 72(5):864-73. PubMed ID: 12429708
[TBL] [Abstract][Full Text] [Related]
15. IgM antibody-dependent cell-mediated cytotoxicity in the Moloney sarcoma virus system: the involvement of T and B lymphocytes as effector cells.
Lamon EW; Whitten HD; Skurzak HM; Andersson B; Lidin B
J Immunol; 1975 Nov; 115(5):1288-94. PubMed ID: 1080777
[TBL] [Abstract][Full Text] [Related]
16. In vitro stimulation and inhibition of tumor cell growth mediated by different lymphoid cell populations.
Norbury KC
Cancer Res; 1977 May; 37(5):1408-15. PubMed ID: 66982
[TBL] [Abstract][Full Text] [Related]
17. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
Barker E; Mokyr MB
Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626
[TBL] [Abstract][Full Text] [Related]
18. [Inhibition of the growth of a syngeneic weakly immunogenic tumor in mice resulting from exposures affecting T lymphocyte activity].
Babadzhanov AS; Buntsevich AM
Biull Eksp Biol Med; 1983 Apr; 95(4):69-71. PubMed ID: 6338967
[TBL] [Abstract][Full Text] [Related]
19. Specific cytostatic effect of lymph node cells from normal and T cell-deficient mice on syngeneic tumor target cells in vitro and its specific abrogation by body fluids from syngeneic tumor-bearing mice.
Chia E; Festenstein H
Eur J Immunol; 1973 Aug; 3(8):483-7. PubMed ID: 4543175
[No Abstract] [Full Text] [Related]
20. Activation of suppressor cells by syngeneic tumor transplants in mice.
Argyris BF
Cancer Res; 1978 May; 38(5):1269-73. PubMed ID: 147732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
